MIGLITOL

Post-LOE

miglitol

R-Pharm US

ANDAORALTABLET

Approved

Feb 2015

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

MIGLITOL (miglitol) by R-Pharm US is alpha glucosidase inhibitors [moa]. First approved in 2015.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

alpha Glucosidase Inhibitors

Pharmacologic Class:

alpha-Glucosidase Inhibitor

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (7)

NCT01099839Phase 1Completed

A Study to Assess Drug-Drug Interaction Between ASP1941 and Miglitol

Started Feb 2010

30 enrolled

Healthy VolunteersPharmacokinetics of ASP1941

NCT00213122Phase 3Completed

Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin

Type 2 Diabetes Mellitus

NCT00213109Phase 3Completed

Open Trial of Miglitol in Type 1 Diabetic Patients With Insulin Treatment

Type 1 Diabetes Mellitus

NCT00334503Phase 3Completed

Open Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide

Type 2 Diabetes Mellitus

NCT00380822Phase 3Completed

Double-Blind Study of Miglitol in Japanese With type2 Diabetes

Type 2 Diabetes Mellitus

Worked on MIGLITOL at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.